Zylox-Tonbridge Medical Technology Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jonathon Zhao
Algemeen directeur
CN¥17.4m
Totale compensatie
| Percentage CEO-salaris | 17.3% |
| Dienstverband CEO | 12yrs |
| Eigendom CEO | 12.9% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 3.7yrs |
Recente managementupdates
Recent updates
Market Participants Recognise Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Revenues Pushing Shares 27% Higher
Oct 02
Solid Earnings Reflect Zylox-Tonbridge Medical Technology's (HKG:2190) Strength As A Business
Sep 27Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Shares May Have Run Too Fast Too Soon
Apr 23Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Shares Could Be 48% Below Their Intrinsic Value Estimate
Jan 18Does This Valuation Of Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Imply Investors Are Overpaying?
Sep 21There's Reason For Concern Over Zylox-Tonbridge Medical Technology Co., Ltd.'s (HKG:2190) Price
Aug 03We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jun 30Is Zylox-Tonbridge Medical Technology Co., Ltd. (HKG:2190) Trading At A 45% Discount?
Mar 08We're Not Very Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Rate
Jan 19Here's Why We're Not Too Worried About Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Jul 06We're Hopeful That Zylox-Tonbridge Medical Technology (HKG:2190) Will Use Its Cash Wisely
Jan 27Here's Why We're Not At All Concerned With Zylox-Tonbridge Medical Technology's (HKG:2190) Cash Burn Situation
Oct 05Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥26m |
| Mar 31 2024 | n/a | n/a | -CN¥27m |
| Dec 31 2023 | CN¥17m | CN¥3m | -CN¥79m |
| Sep 30 2023 | n/a | n/a | -CN¥101m |
| Jun 30 2023 | n/a | n/a | -CN¥124m |
| Mar 31 2023 | n/a | n/a | -CN¥119m |
| Dec 31 2022 | CN¥21m | CN¥3m | -CN¥114m |
| Sep 30 2022 | n/a | n/a | -CN¥135m |
| Jun 30 2022 | n/a | n/a | -CN¥155m |
| Mar 31 2022 | n/a | n/a | -CN¥178m |
| Dec 31 2021 | CN¥16m | CN¥2m | -CN¥200m |
| Sep 30 2021 | n/a | n/a | -CN¥168m |
| Jun 30 2021 | n/a | n/a | -CN¥135m |
| Mar 31 2021 | n/a | n/a | -CN¥118m |
| Dec 31 2020 | CN¥10m | CN¥1m | -CN¥100m |
| Dec 31 2019 | CN¥1m | CN¥746k | -CN¥67m |
Compensatie versus markt: De totale vergoeding ($USD 2.40M ) Jonathon } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 390.12K ).
Compensatie versus inkomsten: De vergoeding van Jonathon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jonathon Zhao (57 yo)
12yrs
Tenure
CN¥17,389,000
Compensatie
Dr. Zhong Zhao also known as Jonathon, serves as Director of Avinger, Inc. since March 04, 2024. He is Founder of Zylox-Tonbridge Medical Technology Co., Ltd. and serves as its Chairman since November 06,...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 12yrs | CN¥17.39m | 12.95% HK$ 458.6m | |
| Senior VP of Sales & Marketing and Executive Director | 6.7yrs | CN¥10.53m | 0.12% HK$ 4.4m | |
| Senior VP | 5.8yrs | CN¥8.37m | 1.58% HK$ 56.1m | |
| Independent Non-Executive Director | 3.7yrs | CN¥200.00k | geen gegevens | |
| Non-Executive Director | 3.9yrs | geen gegevens | geen gegevens | |
| Non-Executive Director | 4.1yrs | geen gegevens | geen gegevens | |
| Non Executive Director | 2.5yrs | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | 3.7yrs | CN¥200.00k | geen gegevens | |
| Employee Supervisor | 3.7yrs | geen gegevens | geen gegevens | |
| Supervisor | 2.5yrs | geen gegevens | geen gegevens | |
| Chairman of the Board of Supervisors | less than a year | geen gegevens | geen gegevens | |
| Independent Non-Executive Director | less than a year | geen gegevens | geen gegevens |
3.7yrs
Gemiddelde duur
51yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 2190 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.7 jaar).